hygroton 50mg tablets
alliance pharmaceuticals ltd - chlortalidone - oral tablet - 50mg
hygroton k
novartis new zealand ltd - chlortalidone 25mg; potassium chloride 500mg - tablet - 25mg/500mg - active: chlortalidone 25mg potassium chloride 500mg
tenoretic 100mg/25mg film-coated tablets
astrazeneca uk limited - chlortalidone; atenolol - film-coated tablet - chlortalidone 25 mg; atenolol 100 mg - beta blocking agents
stronger neo-minophagen c 53mg/20ml(40mg/20ml)+400mg/20ml+22,29mg/20ml (20mg/20ml) solution for injection
minophagen pharmaceutical co. - monoammonium glycyrrhizinate (glycyrrhizic acid), glycine, l-cysteine hydrochloride hydrate (l-cysteine hydrochloride) - solution for injection - 53mg/20ml(40mg/20ml)+400mg/20ml+22,29mg/20ml (20mg/20ml)
tenoretic tablet, film coated 100mg/25mg
astrazeneca ab se-151 85, södertälje, sweden - chlortalidone, atenolol - film-coated tablet - chlortalidone 25 mg atenolol 100 mg - beta blocking agents
stronger neo-minophagen c 53mg/20ml(40mg/20ml)+400mg/20ml+22,29mg/20ml (20mg/20ml) solution for injection
minophagen pharmaceutical co. - monoammonium glycyrrhizinate (glycyrrhizic acid), glycine, l-cysteine hydrochloride hydrate (l-cysteine hydrochloride) - solution for injection - 53mg/20ml(40mg/20ml)+400mg/20ml+22,29mg/20ml (20mg/20ml)
stronger neo-minophagen c solution for injection
minophagen pharmaceutical co. - monoammonium glycyrrhizinate (glycyrrhizic acid), glycine, l-cysteine hydrochloride hydrate (l-cysteine hydrochloride) - solution for injection - 53mg/20ml(40mg/20ml)+ 400mg/20ml+ 22,29mg/20ml (20mg/20ml)
hylaton 12.5mg tablets
morningside healthcare ltd - chlortalidone - oral tablet - 12.5mg
hylaton 50mg tablets
morningside healthcare ltd - chlortalidone - oral tablet - 50mg
hygroton
aft pharmaceuticals ltd - chlortalidone 25mg; - tablet - 25 mg - active: chlortalidone 25mg excipient: colloidal silicon dioxide iron oxide red iron oxide yellow lactose monohydrate magnesium stearate maize starch purified talc - arterial hypertension, essential or nephrogenic or isolated systolic, as primary therapy or in combination with other antihypertensive agents. stable, chronic heart failure of mild to moderate degree (new york heart association, nhya: functional class ii or iii). - oedema of specific origin - oedema due to peripheral (chronic) venous insufficiency; short-term therapy if physical measures prove insufficient. - fluid retention in premenstrual syndrome only if the gain in weight is the main symptom and is well documented. - ascites due to cirrhosis of the liver in stable patients under close control. - oedema due to nephrotic syndrome. - prophylaxis against recurrent calcium oxalate calculi in patients with idiopathic, normocalcaemic hypercalciuria.